Who Paid My Doc
Nicole Habel
Cardiovascular Disease Middlebury, VT Medical Doctor
NPI 1881081370 CMS profile 5706142
115 Porter Dr, Middlebury, VT 05753
General payments
$129,533
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$40,461
Through program year 2025, Nicole Habel of Middlebury, VT is reported in the CMS Open Payments database as having received $129,533 across 141 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $40,461 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $26,128 | 84 | |
| 2024 | General | $3,708 | 19 | |
| 2023 | General | $22,675 | 12 | |
| 2022 | General | $52,934 | 15 | |
| 2021 | General | $23,404 | 5 | |
| 2020 | General | $263 | 2 | |
| 2019 | General | $420 | 4 |
Beside peers
- Nicole Habel
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Nicole Habel were reported at $26,128. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Nicole Habel | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $420 | $450 | $127–$1,392 | $163 |
| 2020 | $263 | $242 | $77–$751 | $114 |
| 2021 | $23,404 | $335 | $101–$1,037 | $132 |
| 2022 | $52,934 | $395 | $121–$1,211 | $149 |
| 2023 | $22,675 | $443 | $136–$1,283 | $160 |
| 2024 | $3,708 | $450 | $136–$1,323 | $164 |
| 2025 | $26,128 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
122
Drug cost
$34,131
Branded share of claims
21.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 26 | $31,927 | |
| Dofetilide | Generic | 11 | $1,640 | |
| Amlodipine Besylate | Generic | 19 | $139 | |
| Carvedilol | Generic | 13 | $123 | |
| Metoprolol Succinate | Generic | 11 | $114 | |
| Atorvastatin Calcium | Generic | 17 | $75 | |
| Pantoprazole Sodium | Generic | 13 | $71 | |
| Hydrochlorothiazide | Generic | 12 | $44 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 40 billing codesPaid by Medicare
$31,329
Medicare patients
447
Services billed
597
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Atrial fibrillation | 47% | |
| Arthritis | 46% | |
| Ischemic heart disease | 43% | |
| Heart failure | 38% | |
| Depression | 28% | |
| Diabetes | 27% | |
| Chronic kidney disease | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
141 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Vermont
Harold Dauerman
Cardiovascular Disease · Burlington, VT
Daniel Lustgarten
Cardiovascular Disease · Burlington, VT
Shubash Adhikari
Cardiovascular Disease · Burlington, VT
Adipong Brickshawana
Cardiovascular Disease · Burlington, VT
Thomas Gilliland
Cardiovascular Disease · Burlington, VT
Martin Lewinter
Cardiovascular Disease · South Burlington, VT
Related records
Cardiovascular Disease in Vermont
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Vermont
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.